**SGLT-2 Inhibitors:**
*A New Mechanism for Glycemic Control*

Edward C. Chao, DO

Type 2 diabetes is a progressive, chronic metabolic disease characterized by hyperglycemia. Beyond being a diagnostic marker, elevated glucose is a key factor in the two abnormalities that are at the core of type 2 diabetes: pancreatic β-cell failure and insulin resistance. Chronic hyperglycemia can induce apoptosis of β-cells that is not countered by a compensatory increase in β-cell neogenesis and can lead to decreased insulin gene transcription. The detrimental effect of excessive glucose concentrations is referred to as “glucotoxicity.”

Despite therapeutic advances, the incidence and prevalence of diabetes continue to surge. An estimated 25.8 million people in the United States have diabetes. The incidence could triple to one in three by 2050. Worldwide, the number of individuals with diabetes is projected to rise from 366 million in 2011 to 552 million by 2030, which is the equivalent of approximately three new cases being diagnosed every 10 seconds.

Type 2 diabetes doubles the risk of cardiovascular disease, and macrovascular complications (myocardial infarction and stroke) are a common cause of death in patients with type 2 diabetes. The U.K. Prospective Diabetes Study showed that every 1% absolute decline in mean A1C was associated with a 37% reduction in the risk of microvascular complications and a 21% reduction in the risk of any diabetes-related complication or death. Diabetes also exacts a tremendous economic burden; in the United States, direct and indirect costs totaled $174 billion in 2007.

Meeting treatment goals is elusive for many people with diabetes. Data from the National Health and Nutrition Examination Survey from 2003 to 2006 showed that only 57.1% of adults with diagnosed diabetes achieved an A1C < 7%, 45.5% had a blood pressure level < 130/80 mmHg, and 46.5% had an LDL cholesterol level < 100 mg/dl. Only 12.2% of people with diabetes reached all three goals.

There are multiple barriers to achieving optimal glycemic control. The pathophysiology of diabetes is complex and involves multiple defects: β-cell failure (decreased insulin secretion); insulin resistance in muscle, brain, and liver; increased glucagon secretion in α-cells; increased lipolysis in adipose tissue; incretin deficiency and resistance in the gastrointestinal (GI) tract; and increased glucose reabsorption in the kidney. Other obstacles include clinical inertia, or the failure to start or intensify therapy when clinically indicated. There is some evidence that patients with type 2 diabetes who have lower medication adherence are less likely to undergo treatment intensification. Reaching glycemic targets may also be hampered by aversion to adding insulin or implementing lifestyle changes. Barriers such as cost and formulary restrictions also present challenges.

Current medications for type 2 diabetes have potential adverse effects; sulfonylureas and insulin, for example, can cause hypoglycemia and weight gain. Thus, the search continues for novel therapeutic agents that can help patients avoid these limiting side effects while providing glycemic control.

Although the concept of the kidney playing a significant role in glucose balance is not new, only recently has this organ been considered a potential therapeutic target. Sodium-glucose cotransporters (SGLTs), namely SGLT-1 and SGLT-2, facilitate reabsorption of glucose back into the plasma. Inhibiting this process promotes glucosuria and thus reduces blood glucose. This review describes the mechanism of action of this new

**IN BRIEF**

Glucosuria, the presence of glucose in the urine, has long been regarded as a consequence of uncontrolled diabetes. However, glucose excretion can be induced by blocking the activity of the renal sodium-glucose cotransporter 2 (SGLT-2). This mechanism corrects hyperglycemia independently of insulin. This article provides an overview of the paradigm shift that triggered the development of the SGLT-2 inhibitor class of agents and summarizes the available evidence from clinical studies to date.
class of treatment for type 2 diabetes, as well as published data on its efficacy and safety.

**Role of the Kidney in Glucose Homeostasis**

Despite wide fluctuations in the daily supply of glucose and the body’s demand for it, homeostatic mechanisms maintain plasma glucose levels within a narrow range, with average levels of ~90–100 mg/dl in a 24-hour period. The kidney’s crucial role in maintaining glucose balance was first described as early as 1938. Along with the liver, the kidney supplies glucose during periods of fasting. The renal contribution to gluconeogenesis is ~15–55 g/day, or 20–25% of the glucose released into the circulation after an overnight fast.

The reabsorption of glucose filtered into the glomerular filtrate is the primary mechanism by which the kidney influences glucose homeostasis. Glucose excretion in urine is the net difference between the amount of glucose filtered by the kidney and the amount reabsorbed. In healthy individuals, the kidney contributes significantly to glucose homeostasis by reabsorbing essentially all of the ~180 g of glucose that it filters per day. Individuals without diabetes thus have very little or no glucose present in the urine.

Reabsorption occurs in the proximal convoluted tubule (PCT) and is carried out by two isoforms of SGLT. SGLT-2 is located in the S1 and S2 segments of the PCT and has a high capacity but low affinity for glucose transport. In healthy individuals, it reabsorbs ~90% of filtered glucose (Figure 1). SGLT-1 governs glucose transport in the S3 segment and is a low-capacity, high-affinity glucose transporter that reabsorbs the remaining 10% of the filtered glucose. The active transport of glucose is linked to downhill sodium transport, which is maintained by active extrusion of sodium across the basolateral surface into the intracellular fluid (Figure 2).

The renal glucose threshold (RTG) is the plasma glucose concentration above which the SGLT capacity becomes saturated and urinary glucose excretion (UGE) occurs. It is estimated to occur at a plasma glucose concentration of ~200 mg/dl (Figure 3). The actual threshold is not abrupt and differs from the theoretical threshold for both the reabsorption and excretion curves (Figure 3). One

---

**Figure 1. Renal glucose handling.** In healthy individuals, the vast majority of the glucose filtered by the kidney is reabsorbed by SGLT-2 in the S1 and S2 segments of the proximal convoluted tubule, and the remaining glucose is reabsorbed by SGLT-1 in the S3 segment.

**Figure 2. SGLT-2 mediates glucose reabsorption in the kidney.** SGLT-2 catalyzes the active transport of glucose (against a concentration gradient) across the luminal membrane by coupling it with the downhill transport of Na+. The inward Na+ gradient across the luminal epithelium is maintained by active extrusion of Na+ across the basolateral surface into the intracellular fluid. Glucose diffuses out of the cell down a concentration gradient via the basolateral facilitative transporter GLUT2.

Adapted from Ref. 20.
The rate of renal glucose reabsorption is elevated in people with type 2 diabetes; the $T_{max}$ is increased by 20–40% compared to healthy individuals. What was once an adaptive response to ensure sufficient caloric intake thus becomes the opposite: a maladaptive action that fuels further increases in plasma glucose. Both expression and function of SGLT-2 are upregulated in people with type 2 diabetes.

**Introduction to SGLT-2 Inhibitors**

In the 2nd century, the Greek physician Areataeus postulated that diabetes was caused by a derangement in the kidney. Phlorizin, the first known SGLT inhibitor, was isolated from the root bark of apple trees.

Phlorizin was not developed for use in humans because of its low bioavailability (~15%) and its action on SGLT-1, which can result in GI side effects, including diarrhea. Other SGLT-2 inhibitors, such as sergliflozin, did not reach advanced stages of clinical development for reasons related to their pharmacokinetic profiles (i.e., their susceptibility to hydrolysis by GI tract enzymes resulted in relatively short half-lives and poor bioavailability).

Canagliflozin has been approved in the United States, and dapagliflozin has been approved in Europe. Several other SGLT-2 inhibitors are in development (Table 1).

**Mechanism of Action and Potential Advantages**

By lowering the renal threshold for glucose excretion, SGLT-2 inhibitors suppress renal glucose reabsorption and thereby increase UGE. Hyperglycemia is thus ameliorated. However, SGLT-2 inhibitors inhibit reabsorption of only ~30–50% of the glucose filtered by the kidney. The reasons for this are unclear. One hypothesis is that SGLT-2 inhibitors may be actively secreted into the PCT such that the amount of SGLT-2 inhibitor in the PCT is limited by saturation of renal secretion of the inhibitor at high doses, and, depending on the site of secretion, the inhibitors may be unable to act on upstream SGLT-2.

SGLT-2 inhibition offers several putative advantages. Acting independently of insulin, these agents should not confer a risk of hypoglycemia and could be employed as monotherapy or in combination with other agents. Given their mechanism of action, these agents should be effective in patients with any degree...
of insulin resistance or β-cell function. They should also be associated with weight loss resulting from the loss of glucose (calories) in urine and glucose-induced osmotic diuresis. Their mild osmotic diuretic effect could potentially also reduce blood pressure. Taken together, these effects may have a beneficial impact on cardiovascular outcomes.

Inducing UGE initially appears to be a counterintuitive strategy for treatment of patients with type 2 diabetes because it employs what was once thought of only as a signal of uncontrolled diabetes. This conceptual leap from symptom to tool for studying physiology to potential treatment will be further examined.

**Clinical Studies**

SGLT-2 inhibitors have improved glycemic control as monotherapy in patients with type 2 diabetes in phase 2 and 3 clinical trials. Placebo-adjusted reductions in A1C of up to 1.2% have been reported in studies ranging from 4 weeks to 90 weeks in duration, in addition to decreased fasting plasma glucose and postprandial glucose. Phase 2 and 3 clinical trials of SGLT-2 inhibitors used as add-on therapy demonstrated improved glycemic control with low rates of hypoglycemia. An SGLT-2 inhibitor added to metformin, or to metformin plus a sulfonlurea resulted in absolute reductions in A1C of up to 1% from a baseline of 8%. A1C declined by 2% in one study of dapagliflozin added to metformin, in which patients had elevated baseline A1C levels (~9%). Reductions in A1C have also been reported when SGLT-2 inhibitors were added to pioglitazone, glimepiride (up to 0.8%), insulin (up to 1%), or insulin plus oral antidiabetic agents (up to 0.7%). Dapagliflozin has been shown to be effective in patients with early type 2 diabetes (i.e., treatment-naive patients), as well as in patients dependent on insulin plus insulin sensitizers. A pooled analysis of data from five phase 3 studies of dapagliflozin demonstrated that higher baseline A1C levels were associated with greater reductions in A1C. For example, at 24 weeks, dapagliflozin lowered A1C by 0.44% (placebo-adjusted) in patients with a baseline A1C < 8.0%, by 0.54% in patients with baseline A1C ≥ 8.0 to < 9.0%, and by 1.01% in patients with baseline A1C ≥ 9%.

Because the glomerular filtration rate (GFR) is a factor in determining the extent to which SGLT-2 inhibitors can produce glucosuria, their efficacy would be expected to be reduced in patients with impaired renal function. Attenuated glucosuria associated with ipragliflozin was observed in patients with type 2 diabetes and moderate or severe renal impairment (estimated GFR [eGFR] 15–59 ml/min/1.73 m²) compared to those with mild renal impairment or normal renal function. UGE decreased by 42–90% in patients with type 2 diabetes and renal impairment (eGFR 30–89 ml/min/1.73 m²) receiving dapagliflozin compared to patients with type 2 diabetes and normal renal function.

Clinical trials of SGLT-2 inhibitors in patients with type 2 diabetes and renal impairment have shown mixed results in their ability to reduce A1C. In a study involving patients with type 2 diabetes and moderate renal impairment (eGFR 30–60 ml/min/1.73 m²), reductions in A1C were observed with dapagliflozin has been shown to be effective in patients with early type 2 diabetes (i.e., treatment-naive patients), as well as in patients dependent on insulin plus insulin sensitizers. A pooled analysis of data from five phase 3 studies of dapagliflozin demonstrated that higher baseline A1C levels were associated with greater reductions in A1C. For example, at 24 weeks, dapagliflozin lowered A1C by 0.44% (placebo-adjusted) in patients with a baseline A1C < 8.0%, by 0.54% in patients with baseline A1C ≥ 8.0 to < 9.0%, and by 1.01% in patients with baseline A1C ≥ 9%.

Because the glomerular filtration rate (GFR) is a factor in determining the extent to which SGLT-2 inhibitors can produce glucosuria, their efficacy would be expected to be reduced in patients with impaired renal function. Attenuated glucosuria associated with ipragliflozin was observed in patients with type 2 diabetes and moderate or severe renal impairment (estimated GFR [eGFR] 15–59 ml/min/1.73 m²) compared to those with mild renal impairment or normal renal function. UGE decreased by 42–90% in patients with type 2 diabetes and renal impairment (eGFR 30–89 ml/min/1.73 m²) receiving dapagliflozin compared to patients with type 2 diabetes and normal renal function.

Clinical trials of SGLT-2 inhibitors in patients with type 2 diabetes and renal impairment have shown mixed results in their ability to reduce A1C. In a study involving patients with type 2 diabetes and moderate renal impairment (eGFR 30–60 ml/min/1.73 m²), reductions in A1C were observed with dapa-

---

**Table 1. SGLT-2 Inhibitors and Phase of Development**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Latest Stage</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dapagliflozin</td>
<td>Approved by European Medicines Agency</td>
<td>Bristol-Myers Squibb, AstraZeneca</td>
</tr>
<tr>
<td>Canagliflozin</td>
<td>Approved by U.S. Food and Drug Administration</td>
<td>Johnson &amp; Johnson, Mitsubishi Tanabe</td>
</tr>
<tr>
<td>Empagliflozin</td>
<td>Phase 3</td>
<td>Boehringer Ingelheim, Eli Lilly</td>
</tr>
<tr>
<td>Ipragliflozin</td>
<td>Phase 3</td>
<td>Astellas, Kotobuki</td>
</tr>
<tr>
<td>Tofogliflozin</td>
<td>Phase 3</td>
<td>Chugai</td>
</tr>
<tr>
<td>Luseogliflozin</td>
<td>Phase 3</td>
<td>Taisho</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>Phase 2</td>
<td>Pfizer</td>
</tr>
<tr>
<td>LX 4211</td>
<td>Phase 2</td>
<td>Lexicon</td>
</tr>
<tr>
<td>EGT0001442</td>
<td>Phase 2</td>
<td>Theracos</td>
</tr>
<tr>
<td>GW 869682</td>
<td>Phase 2</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>ISIS 388626</td>
<td>Phase 1</td>
<td>Isis</td>
</tr>
</tbody>
</table>
gliflozin, 5 and 10 mg, but were not significantly different from placebo. However, in a phase 3 study of canagliflozin in patients with type 2 diabetes and moderate renal impairment (eGFR 30–50 ml/min/1.73 m²), A1C was significantly lower with canagliflozin, 100 and 300 mg, compared to placebo at week 26. Further data are required to establish the efficacy of SGLT-2 inhibitors in patients with type 2 diabetes and renal impairment.

SGLT-2 inhibitors have produced weight reductions of up to 4.7 kg in phase 2 and 3 clinical trials when administered as monotherapy or as add-on therapy to metformin, a sulfonylurea, or insulin over study periods ranging from 4 to 104 weeks. Canagliflozin, 5 and 10 mg, but were not significantly different from placebo. In most cases, genital infections seen in these studies responded to routine management, usually with azoles, and did not lead to drug discontinuation.

Small increases in hematocrit of 1–2% have been observed in some studies of SGLT-2 inhibitors, consistent with mild volume contraction, although urine volume rises only slightly; electrolytes, including sodium and potassium, are not significantly lost. There is no evidence of deleterious effects such as decreased hematocrit that would lead to orthostatic hypotension or renal impairment.

From 11 phase 3 clinical trials of dapagliflozin, 9 cases of bladder cancer out of 5,478 patients administered dapagliflozin (0.16%) and 9 cases of breast cancer out of 2,223 female patients (0.4%) were detected, compared to the placebo groups, in which 1 of 3,156 subjects had bladder cancer (0.03%) and 1 of 1,053 female patients had breast cancer (0.09%). The number of cases was too small to establish causality. Half of the bladder cancer cases were found within 6–12 months of entering the trial and were in more advanced stages of this cancer. Six of the nine patients with bladder cancer demonstrated hematuria at the beginning of the trial. The increased incidence of UTIs in the dapagliflozin groups may have produced a detection bias for bladder cancer. Animal studies with doses up to 100 times the clinical dosage of dapagliflozin did not yield observations of carcinogenesis or mutagenesis.

There was one case of suspected drug-induced liver injury in the dapagliflozin arms. At 50 weeks, there was no change in bone mineral density (BMD) of the patients with type 2 diabetes and moderate renal impairment.
density, markers of bone formation, or bone resorption compared to placebo in 165 patients with type 2 diabetes inadequately controlled on metformin who were treated with dapagliflozin. No fractures or sex differences were noted in postmenopausal females or males. Dapagliflozin had a largely neutral effect on blood lipids. Small increases in LDL cholesterol and HDL cholesterol and a small reduction in triglycerides have been observed in some placebo-controlled studies.

Outlook for SGLT-2 Inhibitors
On 19 January 2012, the U.S. Food and Drug Administration (FDA) informed Bristol-Myers Squibb and AstraZeneca that it would not approve dapagliflozin. This decision followed the agency’s Endocrinologic and Metabolic Drugs Advisory Committee recommendation against approval of dapagliflozin by a vote of nine to six. Further data from ongoing clinical trials and possibly data from new studies will be forthcoming. The Committee for Medicinal Products for Human Use of the European Medicines Agency granted marketing authorization for dapagliflozin on 12 November 2012 for use in adults with type 2 diabetes as monotherapy and as combination therapy with other glucose-lowering medicinal products including insulin, together with diet and exercise. On 29 March 2013, the FDA approved canagliflozin to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise.

Several clinical trials of SGLT-2 inhibitors used as monotherapy or in combination with a range of other treatments are ongoing. The largest clinical trial program in progress is for empagliflozin, involving > 14,000 patients. Very large trials of dapagliflozin, canagliflozin, and empagliflozin are ongoing to assess effects on cardiovascular outcomes. In addition, basic science and mechanistic studies are underway to provide a greater understanding of the mechanism of action of SGLT-2 inhibitors and its implications for the pathophysiological processes involved in the progression of type 2 diabetes.

Conclusion
The concept of inhibition of SGLT-2 marks a departure in how diabetes is viewed and approached for treatment. SGLT-2 inhibitors have a novel mechanism of action that is independent of insulin secretion and action. These agents block glucose reabsorption, leading to urinary glucose excretion. The advantages of this approach are reduced hyperglycemia without hypoglycemia, along with weight loss and blood pressure reduction. Data from multiple phase 3 studies of > 5,000 subjects demonstrate these findings. However, increases in UTIs and genitourinary infections have been observed in some studies. SGLT-2 inhibitors could be used as monotherapy or in combination with other medications in patients with type 2 diabetes and potentially earlier in the continuum in those with prediabetes.

Taken together, the clinical evidence to date suggests that SGLT-2 inhibitors hold promise as an important addition to the toolbox of treatment options for type 2 diabetes.

ACKNOWLEDGMENTS
This review was supported by the Veterans Administration San Diego Healthcare System and the University of California, San Diego, School of Medicine. The author was fully responsible for all content and editorial decisions, was involved at all stages of manuscript development, and has approved the final version of this review that reflects the author’s interpretation and conclusions. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Isobel Lever, PhD, and Wendy Morris, MSc, of Fleishman-Hillard Group Limited, London, U.K. Boehringer Ingelheim was given the opportunity to check the data used in the review for factual accuracy only.

REFERENCES


Esposito K, Chiodini P, Bellistella G, Maioirino MI, Guigliano D: Proportion of patients at HbA1c target < 7% with 8 classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 14:228–233, 2012

sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin [Abstract]. Diabetes 61 (Suppl. 1A):LB10 (38-LB), 2012


Widing JP, Mathieu C, Vercruysse F, Usiskin K, Deng L, Canovatchel W. Canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight in subjects with type 2 diabetes (T2D) inadequately controlled with metformin (MET) and sulfonylurea (SU) [Abstract]. Diabetes 61 (Suppl. 1A):A262 (1022-P), 2012


Edward C. Chao, DO, is an associate clinical professor of medicine at the University of California, San Diego, and VA Healthcare System, San Diego.

Note of disclosure: Dr. Chao serves as a member of the advisory board for Janssen Pharmaceuticals, which manufactures an SGLT-2 inhibitor for the treatment of diabetes.